SCM
LAB icon

Sone Capital Management’s Standard BioTools LAB Stock Holding History

Sone Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
2,133,631
+366,850
+21% +$347K 0.13% 99
2026
Q1 		$1.62M Buy
+1,766,781
New +$2.14M 0.14% 95

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Sone Capital Management's LAB Position: Q2 2026 in Review

Sone Capital Management increased its Standard BioTools (LAB) stake by 21% in Q2 2026, buying an estimated $347K and bringing the position to 2,133,631 shares worth $1.76M. The position accounts for 0.13% of the portfolio, ranked #99.

Sone Capital Management first reported a position in LAB in Q1 2026 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Sone Capital Management held 2,133,631 shares of Standard BioTools worth $1.76M as of Q2 2026.
  • Sone Capital Management bought 366,850 Standard BioTools shares in Q2 2026, an estimated $347K.
  • Standard BioTools made up 0.13% of Sone Capital Management's portfolio in Q2 2026, its #99 holding.
  • Sone Capital Management first reported a position in Standard BioTools in Q1 2026 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Sone Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.